- Home
- EAF vs ABEO Comparison
EAF vs ABEO Comparison
Compare EAF & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAF | ABEO |
|---|---|---|
| Founded | 1886 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.0M | 281.0M |
| IPO Year | 1995 | 1980 |
Fundamental Metrics
Financial Performance| Metric | EAF | ABEO |
|---|---|---|
| Price | $15.93 | $5.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $14.25 | ★ $18.20 |
| AVG Volume (30 Days) | 184.7K | ★ 1.2M |
| Earning Date | 02-06-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.29 |
| Revenue | ★ $521,894,000.00 | $400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.64 | $1,589.77 |
| P/E Ratio | ★ N/A | $4.24 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.50 | $3.93 |
| 52 Week High | $20.32 | $7.54 |
Technical Indicators
Market Signals| Indicator | EAF | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 54.42 | 57.58 |
| Support Level | $13.91 | $4.80 |
| Resistance Level | $17.09 | $5.55 |
| Average True Range (ATR) | 1.09 | 0.25 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 51.94 | 73.91 |
Price Performance
Historical ComparisonAbout EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.